These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19088011)

  • 1. Toward a cure for chronic myeloid leukemia.
    O'Hare T; Deininger MW
    Clin Cancer Res; 2008 Dec; 14(24):7971-4. PubMed ID: 19088011
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
    Laneuville P; Dilea C; Yin OQ; Woodman RC; Mestan J; Manley PW
    J Clin Oncol; 2010 Apr; 28(11):e169-71; author reply e172. PubMed ID: 20194843
    [No Abstract]   [Full Text] [Related]  

  • 3. Mutant BCR-ABL clones in chronic myeloid leukemia.
    Mathisen MS; Kantarjian HM; Cortes J; Jabbour E
    Haematologica; 2011 Mar; 96(3):347-9. PubMed ID: 21357713
    [No Abstract]   [Full Text] [Related]  

  • 4. F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
    Oyekunle AA; Castagnetti F; Gugliotta G; Soverini S; Baccarani M; Rosti G
    Leuk Res; 2011 Jul; 35(7):e118-20. PubMed ID: 21489624
    [No Abstract]   [Full Text] [Related]  

  • 5. Chronic myelogenous leukemia progenitors display a genetically unstable personality.
    Rodrigues MS; Sattler M
    J Natl Cancer Inst; 2007 May; 99(9):662-3. PubMed ID: 17470729
    [No Abstract]   [Full Text] [Related]  

  • 6. The second generation of BCR-ABL tyrosine kinase inhibitors.
    Tauchi T; Ohyashiki K
    Int J Hematol; 2006 May; 83(4):294-300. PubMed ID: 16757427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [III. Chronic myeloid leukemia-effectiveness of second generation tyrosine kinase inhibitors for first line treatment of chronic myeloid leukemia-].
    Takahashi N
    Gan To Kagaku Ryoho; 2012 May; 39(5):743-6. PubMed ID: 22701901
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
    Jabbour E; Cortes J; Kantarjian H
    Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell?
    Goldman J
    Lab Hematol; 2004; 10(3):181-4. PubMed ID: 15529444
    [No Abstract]   [Full Text] [Related]  

  • 14. SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia.
    Wang D; Zheng Y; Li J; Wu H; Li X; Tang Y; Liu Y; Li J; Sun R; Zhou Y; Sun J; Yang Y
    Eur J Pharmacol; 2017 Sep; 811():117-124. PubMed ID: 28595903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors.
    Hochhaus A
    Ann Oncol; 2006 Sep; 17 Suppl 10():x274-9. PubMed ID: 17018738
    [No Abstract]   [Full Text] [Related]  

  • 16. Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors.
    Li S; Li D
    J Cell Mol Med; 2007; 11(6):1251-62. PubMed ID: 18205699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
    Quintás-Cardama A; Kantarjian H; Cortes J
    N Engl J Med; 2007 Oct; 357(15):1557; author reply 1557-8. PubMed ID: 17933034
    [No Abstract]   [Full Text] [Related]  

  • 18. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
    Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Goldman JM; Melo JV
    Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic myeloid leukemia: "archetype" of the impact of targeted therapies].
    Nasr R; Bazarbachi A
    Pathol Biol (Paris); 2012 Aug; 60(4):239-45. PubMed ID: 22743097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.